Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction

• मुख्य लेखकों: Asami Sukeishi (लेखक), Kotaro Itohara (लेखक), Atsushi Yonezawa (लेखक), Yuki Sato (लेखक), Katsuyuki Matsumura (लेखक), Yoshiki Katada (लेखक), Takayuki Nakagawa (लेखक), Satoshi Hamada (लेखक), Naoya Tanabe (लेखक), Eishi Imoto (लेखक), Shinichi Kai (लेखक), Toyohiro Hirai (लेखक), Motoko Yanagita (लेखक), Shigeru Ohtsuru (लेखक), Tomohiro Terada (लेखक), Isao Ito (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2022-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Remdesivir, a prodrug of the nucleoside analog GS‐441524, plays a key role in the treatment of coronavirus disease 2019 (COVID‐19). However, owing to limited information on clinical trials and inexperienced clinical use, there is a lack of pharmacokinetic (PK) data in patients with COVID‐19...